SLC3A2 is overexpressed in several cancers, including prostate cancer, bladder cancer, papillary thyroid carcinoma, colorectal carcinoma, and gastric cancer, where its upregulation is linked to worse patient outcomes [174]. This evidence concerns the gene SLC3A2 and cancer.